17 Mar 2026

From the Science Lab to the Medicine Cabinet: How China is Cornering the Market on Our Medicines

The Select Committee on China

The podcast delves into the United States' reliance on China for pharmaceuticals, exploring vulnerabilities in the supply chain and potential national security risks. It highlights China's growing dominance in key starting materials, active pharmaceutical ingredients, and clinical trials. Panelists discuss the fragility of the U.S. biotech industrial base, emphasizing its dependence on investor capital and the potential for a rapid collapse if financial incentives shift towards Chinese competitors. Potential solutions include incentivizing domestic manufacturing, streamlining FDA approval processes, and fostering collaboration with allied countries to de-risk their own supply chains. The discussion also touches on ethical concerns related to clinical trials in China and the need for stricter oversight of foreign trial data.

Outlines

Part 1: Supply Chain Vulnerabilities

Part 2: Domestic Manufacturing Challenges

Part 3: De-risking Strategies

Part 4: Biotech and Clinical Trials

Part 5: Policy and Procurement

Part 6: National Security and Global Exposure

Part 7: Regional Impact and Scaling

Part 8: Military and Allied Cooperation

Part 9: Innovation and Future Outlook

Continue

Preview

How to Get Rich: Every EpisodeNaval

From the Science Lab to the Medicine Cabinet: How China is Cornering the Market on Our Medicines

The Select Committee on China

Part 1: Supply Chain Vulnerabilities

00:03U.S. Reliance on China for Amoxicillin and Medicine Ingredients

U.S. Reliance on China for Amoxicillin and Medicine Ingredients

00:54The Illusion of Diversity and the Geopolitical Risks in Amoxicillin Supply

The Illusion of Diversity and the Geopolitical Risks in Amoxicillin Supply

01:34Quality Gaps and Unknown Origins in Pharmaceutical Manufacturing

Quality Gaps and Unknown Origins in Pharmaceutical Manufacturing

Part 2: Domestic Manufacturing Challenges

02:17The Decline of U.S. Amoxicillin Manufacturing and National Security Concerns

The Decline of U.S. Amoxicillin Manufacturing and National Security Concerns

03:11Preserving U.S. Pharmaceutical Manufacturing Capacity: Defining Domestic Manufacturing

Preserving U.S. Pharmaceutical Manufacturing Capacity: Defining Domestic Manufacturing

04:34Supporting Domestic Production of Critical Medicines as a National Security Priority

Supporting Domestic Production of Critical Medicines as a National Security Priority

Part 3: De-risking Strategies

05:55Defining the Problem: De-risking Chemical Inputs from China

Defining the Problem: De-risking Chemical Inputs from China

07:38Prioritizing Supply Chains and Leveraging French Shoring for Everyday Medicines

Prioritizing Supply Chains and Leveraging French Shoring for Everyday Medicines

08:58Avoiding Unintended Consequences: Congress's Role in Tariff Policy and Procurement

Avoiding Unintended Consequences: Congress's Role in Tariff Policy and Procurement

Part 4: Biotech and Clinical Trials

10:45The Fragility of the U.S. Biotech Industrial Base and the Shift in Financial Incentives

The Fragility of the U.S. Biotech Industrial Base and the Shift in Financial Incentives

13:00Addressing Clinical Trial Migration: FDA Approval Speed and Small-Scale Manufacturing

Addressing Clinical Trial Migration: FDA Approval Speed and Small-Scale Manufacturing

14:29Streamlining Approval Processes and Focusing on Generic Manufacturing

Streamlining Approval Processes and Focusing on Generic Manufacturing

15:30Requiring FDA Inspection of Foreign Trial Data and Its Economic Impact

Requiring FDA Inspection of Foreign Trial Data and Its Economic Impact

17:33FDA Resources for Inspections and the Role of Tariffs

FDA Resources for Inspections and the Role of Tariffs

Part 5: Policy and Procurement

18:51China's Strategic Asset and the Need for Industrial Policy

China's Strategic Asset and the Need for Industrial Policy

20:05The Cost of Federal Procurement Agreements and Controlling Market Access

The Cost of Federal Procurement Agreements and Controlling Market Access

21:53Strategic Tariffs and Smart Industrial Policies for Amoxicillin Production

Strategic Tariffs and Smart Industrial Policies for Amoxicillin Production

Part 6: National Security and Global Exposure

23:30The U.S. as the Patient: Medical Readiness and National Security Problems

The U.S. as the Patient: Medical Readiness and National Security Problems

24:53China's Patient Strategy: Moving Up the Pharmaceutical Value Chain

China's Patient Strategy: Moving Up the Pharmaceutical Value Chain

26:31The Inconsistency of API Exposure Statistics and the Need for Clarity

The Inconsistency of API Exposure Statistics and the Need for Clarity

27:37Mischaracterizations of the Supply Chain and India's Reliance on China

Mischaracterizations of the Supply Chain and India's Reliance on China

29:35Strategic Tariffs and Supporting Indian Manufacturers

Strategic Tariffs and Supporting Indian Manufacturers

Part 7: Regional Impact and Scaling

30:31Pharmaceutical Supply Chains and Economic Opportunity in Northeast Ohio

Pharmaceutical Supply Chains and Economic Opportunity in Northeast Ohio

31:42Short-Term Vulnerabilities and Long-Term Risks to American Leadership

Short-Term Vulnerabilities and Long-Term Risks to American Leadership

32:50On-shoring Essential Medicines and Working with Allies for Everyday Medications

On-shoring Essential Medicines and Working with Allies for Everyday Medications

34:31Working with India to De-risk and the Biggest Barrier to Scaling Production

Working with India to De-risk and the Biggest Barrier to Scaling Production

35:55Safe, Affordable Medicines and the Amoxicillin Shortage of 2022-23

Safe, Affordable Medicines and the Amoxicillin Shortage of 2022-23

37:33Federal Government's Role in Supporting Manufacturers and Preventing Shortages

Federal Government's Role in Supporting Manufacturers and Preventing Shortages

38:54Demand Increases and Payment Mechanisms in the Amoxicillin Shortage

Demand Increases and Payment Mechanisms in the Amoxicillin Shortage

Part 8: Military and Allied Cooperation

40:12The Decision Not to Invest in Chinese Biotech and Concerns About IP

The Decision Not to Invest in Chinese Biotech and Concerns About IP

42:00Military's Dependence on Chinese Supply Chains and Battlefield Medicine

Military's Dependence on Chinese Supply Chains and Battlefield Medicine

43:49DoD's Role in Research and Procurement and Building Civilian Infrastructure

DoD's Role in Research and Procurement and Building Civilian Infrastructure

45:27A Stratified List of Priority Drugs and a Unified Pharmaceutical Strategy

A Stratified List of Priority Drugs and a Unified Pharmaceutical Strategy

46:43Working with Allies and Overcoming the Obsession with Cheap Stuff

Working with Allies and Overcoming the Obsession with Cheap Stuff

Part 9: Innovation and Future Outlook

48:13China's Challenge to U.S. Leadership in Pharmaceutical Innovation